About Stallergenes Greer
Stallergenes Greer is a company based in London (United Kingdom) founded in 2013 was acquired by Waypoint Capital in March 2019.. Stallergenes Greer has completed 1 acquisition, including Adeo Health Science. Stallergenes Greer offers products and services including Allergen Immunotherapy, Diagnosis Solutions, and Precision Medicine. Stallergenes Greer operates in a competitive market with competitors including HOOKIPA Pharma, Valneva, IgGenix, Immunomic Therapeutics and Alladapt, among others.
- Headquarter London, United Kingdom
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Stallergenes Greer Ltd
- Date of Incorporation 06 Dec, 2013
- Jurisdiction LONDON, UNITED KINGDOM
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
- Investors
-
Employee Count
Employee Count
- Investments & Acquisitions
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Stallergenes Greer
Stallergenes Greer offers a comprehensive portfolio of products and services, including Allergen Immunotherapy, Diagnosis Solutions, and Precision Medicine. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Therapy to desensitize patients against allergens for better allergy control.
Methods for identifying allergens in respiratory and food allergies.
Tailored treatments addressing unmet needs in allergy care globally.
Unlock access to complete
Unlock access to complete
Leadership Team
10 people
Data Analysis and Operations Team
5 people
Software Development Team
5 people
Finance and Accounting
4 people
Operations Team
4 people
Product Management Team
3 people
Global Team
3 people
Responsable Team
3 people
Unlock access to complete
Funding Insights of Stallergenes Greer
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Stallergenes Greer
Stallergenes Greer has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include B-FLEXION. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
B-FLEXION is recognized as a private entrepreneurial investment firm.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Stallergenes Greer
Stallergenes Greer has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Adeo Health Science. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Manufactures proprietary baby food to safely introduce eight allergens.
|
2017 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Stallergenes Greer
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Stallergenes Greer Comparisons
Competitors of Stallergenes Greer
Stallergenes Greer operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as HOOKIPA Pharma, Valneva, IgGenix, Immunomic Therapeutics and Alladapt, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| domain | founded_year | HQ Location |
Prophylactic vaccines for infectious diseases are developed and advanced.
|
|
| domain | founded_year | HQ Location |
Therapeutic solutions for food allergies are developed via antibody platforms.
|
|
| domain | founded_year | HQ Location |
Immunomic Therapeutics is engaged in developing nucleic acid immunotherapy platforms.
|
|
| domain | founded_year | HQ Location |
Therapeutics for treating food allergies are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Stallergenes Greer
Frequently Asked Questions about Stallergenes Greer
When was Stallergenes Greer founded?
Stallergenes Greer was founded in 2013.
Where is Stallergenes Greer located?
Stallergenes Greer is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Who is the current CEO of Stallergenes Greer?
Michele Antonelli is the current CEO of Stallergenes Greer.
What does Stallergenes Greer do?
Stallergenes Greer is developing allergen immunotherapy (vaccine) for respiratory allergies. Its drug pipeline STAGR 320 (HDM) for Allergic Rhinitis (Phase 3 in EuropeUS and approved in Japan) and for HDM) Allergic Asthma (Phase 2); STAGR 120 for (Jap.Cedar) Allergic Rhinitis (Phase 2); JPSTAGR SAIL SLIT(Ragweed) Allergic Rhinitis (Phase 3).
Who are the top competitors of Stallergenes Greer?
Stallergenes Greer's top competitors include HOOKIPA Pharma, Valneva and IgGenix.
What products or services does Stallergenes Greer offer?
Stallergenes Greer offers Allergen Immunotherapy, Diagnosis Solutions, and Precision Medicine.
How many acquisitions has Stallergenes Greer made?
Stallergenes Greer has made 1 acquisition, including Adeo Health Science.
Who are Stallergenes Greer's investors?
Stallergenes Greer has 1 investor. Key investors include B-FLEXION.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.